Facebook-f X-twitter Linkedin-in Instagram Youtube

Landing Page

All Content

Investors Eye Gold and Silver, but Palladium’s Surge is Demanding Attention

Gold and silver may be dominating headlines with record highs, but palladium is quietly staging a comeback. Prices are up more than 34% this year, driven by industrial demand and...

Trilogy Metals Shares Surge Over 200% After U.S. Takes 10% Stake

Trilogy Metals shares skyrocketed after the U.S. government announced a $35.6 million investment, signaling a renewed federal commitment to securing America’s critical mineral supply chains and advancing domestic resource development...

Pharma Stocks Split as Trump Unveils 100% Drug Tariff

Trump’s 100% tariff on foreign-made branded drugs has shaken markets, with analysts warning the impact won’t be evenly felt....

Should You Invest in Gold? 7 Experts Weigh In

Gold futures have surged past $3,700 an ounce, prompting experts to weigh in on whether investors should jump in—or has that ship sailed?...

Nvidia to Invest $100B in OpenAI, Cementing Partnership

Nvidia and OpenAI are joining forces in a landmark $100 billion partnership, combining Nvidia’s GPU leadership with OpenAI’s AI development to shape the next era of artificial intelligence....

Next-Generation Mining Maintenance Exposes Skills Gap

Once dominated by grease and wrenches, mining maintenance is now data-driven, AI-powered, and remote—but the workforce is struggling to keep up....

Buy, Sell, or Hold: Hims & Hers Stock Surges 64%

The past six months have been a windfall for Hims & Hers Health’s shareholders as the stock surged 64%. Is now the right time to buy HIMS? Or is this...

This Biotech’s Phase 3 Results Could Be a Game-Changer for Investors

The next few weeks for aTyr Pharma will reveal a great deal about this company’s future. aTyr Pharma is set to transform treatment for pulmonary sarcoidosis and unlock blockbuster potential....

Top Tip: Mining Multibagger, Ready to Run

U.S. junior critical mineral miner, ARES STRATEGIC MINING (CSE: ARS | FRA: N8I1 | OTC: ARSMF), is about to have its long-awaited Cinderella moment. For 5 years now, ARES has...

en_USEnglish
de_DEGerman en_USEnglish